Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. It operates through the following segments: Pharmaceuticals and Others. The Pharmaceuticals segment includes prescription ophthalmic drugs, anti-rheumatic pharmaceuticals, and over-the-counter products. The Others segment offers medical equipment and devices. The company was founded by Kenkichi Tagushi in 1890 and is headquartered in Osaka, Japan.

Oncotherapy science (OTS) is“ to deliver cancer therapeutics and treatments with higher efficacy and fewer side effects to patients suffering from cancer as soon as possible, and to overcome the fight against cancer. Was established with the aim of OTS brought Professor Genomix (Science that handles genetic information systematically) as a pioneer in the medical field with Prof. Atsushi Nakamura (Director, Cancer Precision Medical Research Center, Institute of Cancer, Professor Emeritus, The University of Tokyo, Professor Emeritus of Chicago University) Joint research to identify target molecules suitable for cancer drug development based on comprehensive gene expression analysis, and promote research and development of small molecule drugs, cancer peptide vaccines and antibody drugs for those targets.

The Georgia Tech Research Corp. provides research and technology support services. Its services include accounting and reports, researcher and operational support services. The comapny was founded by Preston S. Arkwright, Fuller E. Callaway, Jr. and Monie A. Ferst on April 13, 1937 and is headquartered in Atlanta, GA.

Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient’s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.

iScience Interventionalâ„¢ discovers and develops microcatheter and imaging technologies that enable ophthalmologists to deliver site-specific ocular therapies. This new category of therapy is called Interventional Ophthalmology. It encompasses microcatheter-based therapies designed to access a wide range of anatomical structures within the eye to aspirate ocular fluids or deliver sterile ophthalmic solutions to the eye.

Gyroscope is a clinical-stage gene therapy company focused on developing therapies and treating diseases of the eye. The company explores the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD), and gene therapy as a mode of treatment delivery. Its lead investigational gene therapy, GT005, is a one-time therapy delivered under the retina. GT005 is designed to restore balance to an overactive complement system by increasing the production of the Complement Factor I protein. GT005 is currently being evaluated in a Phase I/II clinical trial called FOCUS and Phase II clinical trials called EXPLORE and HORIZON. Andrew Lotery, David Kavanagh, and Peter Lachmann co-founded Gyroscope Therapeutics in Stevenage, Herefordshire in 2016.

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.

Ashvattha Therapeutics creates products that selectively target and treat human diseases. Ashvattha enables precision targeting for therapeutics eliminating off-target toxicity, systemic side effects, and immunogenicity seen in other platforms. Ashvattha has a pipeline of nine therapeutics in neurology, oncology, and ophthalmology.

Advanced Ocular Systems Ltd. (AOS) develops refractive surgical devices and pharmaceutical treatments that address unmet needs in segments of ophthalmology. AOS is located in Nedlands, Western Australia.

Implandata Ophthalmic Products is an early stage, privately-held, venture capital funded medical device company based in Hannover, Germany. Implandata Ophthalmic Products is a medical device company offering a new technology for the treatment and management of glaucoma patients. It identifies an underserved area in care of glaucoma patients, creating disruptive solutions for better and more efficient glaucoma therapy, to the benefit of glaucoma patients, families, and care givers by integrating innovative medical technology with information technology. IOP has developed a novel technology for 24 hour measurement of intraocular pressure, by which monitoring and therapy of glaucoma patients will be improved. This solution will allow a more efficient treatment and management of glaucoma patients. Implandata Ophthalmic Products was founded on 2010.

QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada.

Seoul National University Hospital (서울대학교병원) is one of the oldest and biggest hospitals in South Korea. It is a general and teaching hospital of Seoul National University's College of Medicine. Except SNUH Healthcare System Gangnam Center, all branches have an emergency department (ED).

Clearside BioMedical, an ophthalmic company, specializes in the research, development, and commercialization of therapeutic products through an ocular microinjection platform that targets the individual compartments of the eye. It provides a non-surgical application for dosing drugs to distinct eye tissues, such as the retina, trabecular meshwork, and corneal stroma. The company’s CLS1001 is under development for retinal applications through the delivery of therapeutics to the suprachoroidal space. Clearside BioMedical was incorporated in 2011 and is based in Atlanta, Georgia.

Ethicon Endo-Surgery, Inc. manufactures surgical devices and equipments. Its products include the ENDOPATH XCEL access system, CONTOUR curved cutter stapler, HARMONIC ultrasonic cutting and coagulation surgical devices and the MAMMOTOME breast biopsy system. The company was founded in 1992 and is headquartered in Cincinnati, OH.

AskAt, Inc. is a company headquartered in Nagoya, Japan, that develops pharmaceutical products. It was founded in 2013. AskAt, Inc. was acquired by AskAat, Inc. from RaQualia Pharma, Inc. on May 14, 2015.

Doheny Eye Institute is an American private company located in Los Angeles, CA. The firm provides eye care related research and education programs. Marissa Goldberg is currently the CEO of the company.\nThe company says this about itself: For more than 70 years, Doheny Eye Institute has been at the forefront of vision science. From seeking new ways to free blockages that prevent fluid drainage in glaucoma, to replacing retinal cells in age-related macular degeneration, to providing colleagues worldwide with standardized analyses of anatomical changes in the eyes of patients, Doheny clinician-scientists and researchers are changing how people see �� and also how they think about the future of vision. Doheny Eye Institute and UCLA Stein Eye Institute have joined forces to offer the best patient care, vision research, and education. This affiliation combines the strength, reputation, and distinction of two of the nation's top eye institutions to advance vision research, education, and patient care in California.

Part of Novartis AG, Orbit Biomedical Ltd. is a British company located in Stevenage. The firm engages in research and development of biotechnology. It was founded in 2018.

Senju Pharmaceutical Beijing Co. Ltd., part of Senju Pharmaceutical Co., Ltd., is a company headquartered in Beijing, China, that manufactures and distributes pharmaceuticals.